Stockscreener 앱 받기
20.49
3.28%
0.65
시장 영업 전:
20.70
0.21
+1.02%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike - Stock Titan
Director at BioAge Labs (BIOA) receives grant of 22,000 stock options - Stock Titan
BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (BIOA) director receives grant of 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director granted 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director awarded 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (NASDAQ: BIOA) shareholders elect directors and ratify KPMG at 2026 meeting - Stock Titan
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securi - GuruFocus
BioAge Labs eyes key BGE-102 readouts in heart risk and diabetic eye disease - MSN
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease - MarketBeat
BIOA Technical Analysis & Stock Price Forecast - Intellectia AI
BIOA: BGE-102 advances as a differentiated NLRP3 inhibitor with pivotal data expected by year-end - TradingView
BioAge Labs stock gains after positive early data and pipeline plans - MSN
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
BIOA Initiated by Roth Capital -- Price Target Set at $36.00 - GuruFocus
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target - marketscreener.com
Roth MKM Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $36 - Moomoo
Roth/MKM initiates BioAge Labs stock coverage with buy rating - Investing.com
Roth/MKM initiates BioAge Labs stock coverage with buy rating By Investing.com - Investing.com India
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS - Fierce Biotech
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
2.11%
자본화:
|
볼륨(24시간):